In patients with iodine-refractory papillary thyroid cancer, the addition of dabrafenib (Tafinlar) therapy was shown to stimulate radioiodine uptake in thyroid cancer cells, according to a report by Rothenberg et al in Clinical Cancer Research. This approach has the potential advantage of requiring ...
As reported in the Journal of Clinical Oncology by Lyman et al, an ASCO update committee recommended no changes to the 2013 clinical practice guideline for venous thromboembolism (VTE) prophylaxis and treatment after review of 53 new publications in the area that became available between...
Pancreatic cancer affects approximately 46,000 people each year in the United States, and ranks fourth among the leading causes of cancer-related deaths. Only about 6% of individuals with pancreatic cancer will live 5 years after their diagnosis. One reason for this high mortality rate is the lack...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Genentech’s investigational cancer immunotherapy MPDL3280A for the treatment of PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed during or after platinum-based...
Ten months after California legislators enacted a controversial law mandating that radiologists notify women if they have dense breast tissue, University of California (UC), Davis researchers have found that half of primary care physicians are still unfamiliar with the law, and many don't feel...
A large retrospective cohort study of diabetic patients taking metformin, a first-line treatment for type II diabetes, has found that while metformin use was not associated with lower lung cancer risk overall, the risk was 43% lower among diabetic patients who had never smoked. In addition, the...
Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a study by Siddiqui et al published in JAMA. More than 1,000 men participated in the research at the ...
Chemotherapy resistance is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children’s Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy that may prove highly...
The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for patients with Waldenström’s macroglobulinemia, a rare, indolent type of B-cell lymphoma. Ibrutinib is the first therapy indicated specifically for Waldenström’s...
As reported in The Lancet Oncology by Bradley and colleagues, the phase III Radiation Therapy Oncology Group 0617 trial showed no survival benefit of high- vs standard-dose radiotherapy or for addition of cetuximab (Erbitux) to concurrent paclitaxel-carboplatin chemoradiation in patients with...
Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences—with potentially important clinical implications—in human papillomavirus (HPV)-associated head and neck cancers. These findings were reported in Nature. The researchers also uncovered ...
According to researchers at the Johns Hopkins Kimmel Cancer Center, testosterone, which is generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers. The hormone may also reverse resistance to testosterone-blocking drugs used to treat prostate...
A population-based study of women who had undergone surgery for breast cancer has found that many lacked understanding of the basic characteristics of their disease, including stage, grade, and tumor characteristics. Minority patients were less likely than white patients to have the correct...
In a study reported in The New England Journal of Medicine, Genovese et al found that clonal hematopoiesis with somatic mutations is increasingly common with greater age and is associated with increased risk of hematologic cancer. The presence of such clonal hematopoiesis in apparently healthy...
A new analysis opens the door to the discovery of thousands of potential new cancer biomarkers, according to a recent study by Iyer et al published in Nature Genetics. Long Noncoding RNA Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of long...
As reported by Pisansky et al in the Journal of Clinical Oncology, the Radiation Therapy Oncology Group (RTOG) 9910 trial showed no benefit of extending the duration of pre–radiation therapy androgen suppression on survival or disease control among patients with localized prostate cancer....
Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...
Taking a hormonal contraceptive for at least 5 years is associated with a possible increase in women’s risk of developing a glioma, according to a study by Andersen et al published in the British Journal of Clinical Pharmacology. Study Details While little is known about the causes of...
In the phase III SEARCH trial reported in the Journal of Clinical Oncology, Zhu et al found no overall survival benefit of adding erlotinib (Tarceva) to sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma. Study Details In this double-blind trial conducted in 26 countries in...
A genomic study of cancer patients previously treated with chemotherapy or radiation therapy found that TP53 mutations may play a role in the development of treatment-related acute myeloid leukemia (AML) and myelodysplastic syndrome, according to a report by Wong et al in Nature. However, the...
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
Among patients who had an unidentifiable lung nodule detected by a chest computed tomography (CT) scan, testing sputum for a panel of three microRNA (miRNA) biomarkers successfully distinguished early-stage lung cancers from nonmalignant nodules most of the time, according to a study reported by...
ASCO released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer, today, and for the first time announced its cancer Advance of the Year: gains made in the treatment of chronic lymphocytic leukemia (CLL). ASCO credits the improvements in CLL care with the...
New data from the phase II PEAK and phase III PRIME studies support the first-line use of panitumumab (Vectibix) in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) in patients with wild-type RAS metastatic colorectal cancer. The study results were presented during a poster session...
Patients with early-stage breast cancer still undergo imaging for distant metastases despite evidence-based local, national, and international guidelines, and a recommendation from ASCO to avoid such imaging, according to a retrospective review of staging imaging for distant metastases in patients...
After 4.5 years of taking tamoxifen for primary prevention of breast cancer, 46% of women discontinued use, according to research conducted within the Sister Study, a prospective cohort of women who had a sister who had been diagnosed with breast cancer but did not have breast cancer themselves....
In a phase II trial reported in Journal of Clinical Oncology, Dang et al found that the addition of weekly paclitaxel to trastuzumab (Herceptin)/pertuzumab (Perjeta) produced good activity in patients with HER2-positive metastatic breast cancer. Paclitaxel may be a less toxic alternative to...
Among nearly 375,000 U.S. women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biologic differences, according to a study reported by Iqbal et al...
Selenium supplementation of 140 μg/d or more after diagnosis of nonmetastatic prostate cancer may increase risk of prostate cancer mortality, according to a prospective study following 4,459 men initially diagnosed with nonmetastatic prostate cancer in the Health Professionals Follow-up Study...
Although scientists know that all cancers contain a mixture of both rapidly and slowly proliferating cancer cells, which complicates the detection and treatment of patients with cancer and may cause disease relapse long after apparently curative treatment, the circumstances and molecular details of ...
A recent study on the use of minimally invasive surgery for colorectal cancer at National Comprehensive Cancer Network (NCCN) centers has found that although laparoscopic colectomy results in equivalent oncologic outcomes compared to open colectomy, its adoption nationally has been slow. An...
A retrospective review of clinical data on 145 patients with stage I to III rectal cancer indicates that patients who achieved complete response after treatment with chemoradiation and systemic chemotherapy had similar 4-year survival rates regardless of whether they had immediate surgery or...
Even decades after being cured, many cancer survivors face physical and mental challenges resulting from their disease and its treatment, according to a new study reported by Burg et al in Cancer. The findings could help clinicians and other experts develop interventions that are tailored to the...
Patients with locally advanced rectal cancer who receive neoadjuvant radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a 4-year overall survival rate of 85% and 75%, respectively, according to a study reported by Wong et al in the International Journal ...
Approximately 5% to 6% of cases of colorectal cancer are associated with germline mutations conferring an inherited predisposition for disease. As reported by Stoffel et al in the Journal of Clinical Oncology, ASCO has endorsed, with qualifying statements, the European Society for Medical Oncology...
Oral infection with human papillomavirus 16 (HPV16), which is the type of HPV most frequently linked to HPV-driven head and neck cancers, was more likely to persist 12 or more months in men older than 45 than in those younger than 45, according to a study reported by Pierce Campbell et al in...
Retrospective analyses of the ATAC, TEAM, and BIG 1-98 adjuvant endocrine therapy trials in breast cancer have suggested that treatment-emergent endocrine symptoms may be associated with superior survival outcomes. In a study reported in the Journal of Clinical Oncology, Stearns et al found no...
A phase II clinical study of adjuvant paclitaxel and trastuzumab (Herceptin) in women with stage I HER2-positive breast cancer has found the 3-year rate of survival free from invasive disease was 98.7%. The findings may help establish the combination therapy as the first standard treatment approach ...
In a meta-analysis of patients with breast cancer–related lymphedema, low-level laser therapy was associated with reduced limb volume and pain levels, according to a report by Smoot et al in the Journal of Cancer Survivorship. However, the investigators noted that regarding pain management,...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Soligenix’s synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation is reserved for drugs that demonstrate the potential to address an...
In the phase II PALOMA-1/TRIO-18 trial reported in The Lancet Oncology, Finn et al found that the addition of palbociclib to letrozole resulted in significant improvement in progression-free survival as first-line treatment for advanced disease in postmenopausal women with estrogen...
The American Cancer Society’s annual cancer statistics report found that a 22% drop in cancer mortality over 2 decades led to the avoidance of more than 1.5 million cancer deaths that would have occurred if peak rates had persisted. And while cancer death rates have declined in every state,...
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab...
In a study reported in the Journal of Clinical Oncology, Lepore et al found that patients assigned a helper role in a breast cancer Internet support group had worse anxiety/depression symptoms after completion of the intervention than those not assigned a helper role. Study Details In the study,...
A new analysis suggests that women who use bisphosphonates have about half the risk of developing endometrial cancer as women who do not use the drugs. The findings by Alford et al, published early online in Cancer, supports other research that has shown an anticancer effect of this type of...
Today’s approval by the U.S. Food and Drug Administration (FDA) of olaparib (Lynparza) occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian...
Next-generation sequencing in malignant pleural mesothelioma tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival, and cell proliferation pathways, according to a study by Lo Iacono et al in the Journal of Thoracic...
The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes, both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. The findings by Riggi et al, published in Cancer Cell, may lead to new...
In a retrospective study of patients with non–small cell lung cancer (NSCLC) of the superior sulcus, induction chemoradiotherapy followed by resection provided complete or partial response in over 50% of subjects, according to a report by Truntzer et al in Radiation Therapy. However, the...
In a study reported in the Journal of Clinical Oncology, Eskander et al found that rates of 30-day hospital readmission after surgery for advanced ovarian cancer are high and have increased significantly in recent years. In the study, the Surveillance, Epidemiology, and End Results (SEER)-Medicare ...